deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02230189

Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics (ACE)

Mechanistic Study of Epithelial miRNAs and T-cell Recruitment Dynamics That Occur After Allergen Challenge in Patients With Asthma.

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Asthma
Updated 17 times since 2017 Last updated: Jul 19, 2022 Started: Mar 31, 2015 Primary completion: Jan 31, 2020 Completion: Jan 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Asthma, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 17 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Aug 2019 · 9 months · monthly snapshot~Aug 2019 – ~Nov 2020 · 15 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Jan 2022 · 7 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. May 2022 — Sep 2022 [monthly]

    Completed PHASE2

  5. Apr 2022 — May 2022 [monthly]

    Completed PHASE2

Show 12 earlier versions
  1. Feb 2022 — Apr 2022 [monthly]

    Completed PHASE2

  2. Jan 2022 — Feb 2022 [monthly]

    Completed PHASE2

  3. Jun 2021 — Jan 2022 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  4. Mar 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting · Phase: NAPHASE2

  8. Aug 2019 — Nov 2020 [monthly]

    Recruiting NA

  9. Nov 2018 — Aug 2019 [monthly]

    Recruiting NA

  10. Jun 2018 — Nov 2018 [monthly]

    Recruiting NA

  11. Feb 2017 — Jun 2018 [monthly]

    Recruiting NA

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting NA

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Prescott Woodruff
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations